Can Follow-up be Avoided for Probably Benign US Masses with No Enhancement on MRI?
Saved in:
| Title: | Can Follow-up be Avoided for Probably Benign US Masses with No Enhancement on MRI? |
|---|---|
| Authors: | Avendano, Daly1,2 (AUTHOR), Marino, Maria Adele1,3 (AUTHOR), Onishi, Natsuko1 (AUTHOR), Leithner, Doris1,4 (AUTHOR), Martinez, Danny F.1 (AUTHOR), Gibbs, Peter1 (AUTHOR), Jochelson, Maxine1 (AUTHOR), Pinker, Katja1 (AUTHOR), Morris, Elizabeth A.1 (AUTHOR), Sutton, Elizabeth Jane1 (AUTHOR) suttone@mskcc.org |
| Source: | European Radiology. 2021, Vol. 31 Issue 2, p975-982. 8p. 2 Black and White Photographs, 1 Diagram, 2 Charts. |
| Subjects: | Contrast-enhanced magnetic resonance imaging, Adnexal diseases |
| Abstract: | Objectives: To assess whether no enhancement on pre-treatment MRI can rule out malignancy of additional US mass(es) initially assessed as BI-RADS 3 or 4 in women with newly diagnosed breast cancer. Methods: This retrospective study included consecutive women from 2010–2018 with newly diagnosed breast cancer; at least one additional breast mass (distinct from index cancer) assigned a BI-RADS 3 or 4 on US; and a bilateral contrast-enhanced breast MRI performed within 90 days of US. All malignant masses were pathologically proven; benign masses were pathologically proven or defined as showing at least 2 years of imaging stability. Incidence of malignant masses and NPV were calculated on a per-patient level using proportions and exact 95% CIs. Results: In 230 patients with 309 additional masses, 140/309 (45%) masses did not enhance while 169/309 (55%) enhanced on MRI. Of the 140 masses seen in 105 women (mean age, 54 years; range 28–82) with no enhancement on MRI, all had adequate follow-up and 140/140 (100%) were benign, of which 89/140 (63.6%) were pathologically proven and 51/140 (36.4%) demonstrated at least 2 years of imaging stability. Pre-treatment MRI demonstrating no enhancement of US mass correlate(s) had an NPV of 100% (95% CI 96.7–100.0). Conclusions: All BI-RADS 3 and 4 US masses with a non-enhancing correlate on pre-treatment MRI were benign. The incorporation of MRI, when ordered by the referring physician, may decrease unnecessary follow-up imaging and/or biopsy if the initial US BI-RADS assessment and management recommendation were to be retrospectively updated. Key Points: • Of 309 BI-RADS 3 or 4 US masses with a corresponding mass on MRI, 140/309 (45%) demonstrated no enhancement whereas 169/309 (55%) demonstrated enhancement • All masses classified as BI-RADS 3 or 4 on US without enhancement on MRI were benign • MRI can rule out malignancy in non-enhancing US masses with an NPV of 100% [ABSTRACT FROM AUTHOR] |
| Copyright of European Radiology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: egs DbLabel: Engineering Source An: 148164006 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Can Follow-up be Avoided for Probably Benign US Masses with No Enhancement on MRI? – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Avendano%2C+Daly%22">Avendano, Daly</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marino%2C+Maria+Adele%22">Marino, Maria Adele</searchLink><relatesTo>1,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Onishi%2C+Natsuko%22">Onishi, Natsuko</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Leithner%2C+Doris%22">Leithner, Doris</searchLink><relatesTo>1,4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Martinez%2C+Danny+F%2E%22">Martinez, Danny F.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gibbs%2C+Peter%22">Gibbs, Peter</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jochelson%2C+Maxine%22">Jochelson, Maxine</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pinker%2C+Katja%22">Pinker, Katja</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Morris%2C+Elizabeth+A%2E%22">Morris, Elizabeth A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sutton%2C+Elizabeth+Jane%22">Sutton, Elizabeth Jane</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> suttone@mskcc.org</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22European+Radiology%22">European Radiology</searchLink>. 2021, Vol. 31 Issue 2, p975-982. 8p. 2 Black and White Photographs, 1 Diagram, 2 Charts. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Contrast-enhanced+magnetic+resonance+imaging%22">Contrast-enhanced magnetic resonance imaging</searchLink><br /><searchLink fieldCode="DE" term="%22Adnexal+diseases%22">Adnexal diseases</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Objectives: To assess whether no enhancement on pre-treatment MRI can rule out malignancy of additional US mass(es) initially assessed as BI-RADS 3 or 4 in women with newly diagnosed breast cancer. Methods: This retrospective study included consecutive women from 2010–2018 with newly diagnosed breast cancer; at least one additional breast mass (distinct from index cancer) assigned a BI-RADS 3 or 4 on US; and a bilateral contrast-enhanced breast MRI performed within 90 days of US. All malignant masses were pathologically proven; benign masses were pathologically proven or defined as showing at least 2 years of imaging stability. Incidence of malignant masses and NPV were calculated on a per-patient level using proportions and exact 95% CIs. Results: In 230 patients with 309 additional masses, 140/309 (45%) masses did not enhance while 169/309 (55%) enhanced on MRI. Of the 140 masses seen in 105 women (mean age, 54 years; range 28–82) with no enhancement on MRI, all had adequate follow-up and 140/140 (100%) were benign, of which 89/140 (63.6%) were pathologically proven and 51/140 (36.4%) demonstrated at least 2 years of imaging stability. Pre-treatment MRI demonstrating no enhancement of US mass correlate(s) had an NPV of 100% (95% CI 96.7–100.0). Conclusions: All BI-RADS 3 and 4 US masses with a non-enhancing correlate on pre-treatment MRI were benign. The incorporation of MRI, when ordered by the referring physician, may decrease unnecessary follow-up imaging and/or biopsy if the initial US BI-RADS assessment and management recommendation were to be retrospectively updated. Key Points: • Of 309 BI-RADS 3 or 4 US masses with a corresponding mass on MRI, 140/309 (45%) demonstrated no enhancement whereas 169/309 (55%) demonstrated enhancement • All masses classified as BI-RADS 3 or 4 on US without enhancement on MRI were benign • MRI can rule out malignancy in non-enhancing US masses with an NPV of 100% [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of European Radiology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=148164006 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00330-020-07216-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 8 StartPage: 975 Subjects: – SubjectFull: Contrast-enhanced magnetic resonance imaging Type: general – SubjectFull: Adnexal diseases Type: general Titles: – TitleFull: Can Follow-up be Avoided for Probably Benign US Masses with No Enhancement on MRI? Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Avendano, Daly – PersonEntity: Name: NameFull: Marino, Maria Adele – PersonEntity: Name: NameFull: Onishi, Natsuko – PersonEntity: Name: NameFull: Leithner, Doris – PersonEntity: Name: NameFull: Martinez, Danny F. – PersonEntity: Name: NameFull: Gibbs, Peter – PersonEntity: Name: NameFull: Jochelson, Maxine – PersonEntity: Name: NameFull: Pinker, Katja – PersonEntity: Name: NameFull: Morris, Elizabeth A. – PersonEntity: Name: NameFull: Sutton, Elizabeth Jane IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2021 Type: published Y: 2021 Identifiers: – Type: issn-print Value: 09387994 Numbering: – Type: volume Value: 31 – Type: issue Value: 2 Titles: – TitleFull: European Radiology Type: main |
| ResultId | 1 |
